- ►diabetesjournals.org C Hernández, E Carrasco, R Casamitjana, R … - Diabetes Care, 2005 - Am Diabetes Assoc OBJECTIVE—There is growing evidence to indicate that somatostatin could be
added to the list of natural antiangiogenic factors that exist in the vitreous
fluid. In addition, a deficit of intravitreous somatostatin-like ... Cited by 22 - Related articles - BL Direct - All 5 versions
- Free from Publisher R Simó, E Carrasco, A Fonollosa, J García- … - Diabetes care, 2007 - Am Diabetes Assoc Although diabetic macular edema (DME) is the main cause of visual loss in type 2
diabetic patients (1), its pathogenic mechanisms have been much less studied
than proliferative diabetic retinopathy (PDR). The production of both ... Cited by 9 - Related articles - BL Direct - All 5 versions
- Free from Publisher R Simó, A Lecube, L Sararols, J García- … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—SLI in the vitreous fluid was significantly lower in diabetic patients
than in the control group (68 ± 18.7 vs. 193.6 ± 30.8 pg/ml, P < 0.01). The
vitreous SLI-to-plasma SLI ratio was strikingly higher in nondiabetic ... Cited by 18 - Related articles - BL Direct - All 5 versions
- ►endocrinology-journals.org [PDF] A Baldysiak-Figiel, GK Lang, J Kampmeier, … - Journal of Endocrinology, 2004 - Soc Endocrinology Ocular diseases such as proliferative diabetic retinopathy are the major cause
of blindness in industrialized countries. The main pathologic features of these
diseases are hypoxia and overproduction of growth factors resulting in ... Cited by 22 - Related articles - BL Direct - All 6 versions
PM Van Hagen, GS Baarsma, CM Mooy, EM … - EUROPEAN JOURNAL OF ENDOCRINOLOGY- …, 2000 - EFES Introduction Somatostatin is a small neuropeptide that is produced in the
central nervous system, where it acts as a neurotransmitter. This neuropeptide
also has an important role in the neuroendocrine system as an inhibitor of ... Cited by 39 - Related articles - BL Direct - All 13 versions
N Mastrodimou, GN Lambrou, K Thermos - Naunyn-Schmiedeberg's archives of pharmacology, 2005 - Springer Page 1. Naunyn-Schmiedeberg's Arch Pharmacol (2005) 371: 44–53 DOI 10.1007/s00210-
004-1011-9 ORIGINAL ARTICLE Niki Mastrodimou . George N. Lambrou . ... Cited by 14 - Related articles - BL Direct - All 3 versions
JW Sall, DD Klisovic, MS O'Dorisio, SE Katz - Experimental eye research, 2004 - Elsevier Neovascularization stimulated by IGF-1 mediated induction of vascular
endothelial growth factor (VEGF) is one of the leading causes of blindness in
humans. It plays a central role in the pathogenesis of proliferative ... Cited by 32 - Related articles - All 3 versions
C Hernández, R Simó - Expert Opinion in Investigational Drugs, 2007 - informahealthcare.com Proliferative diabetic retinopathy (PDR) demands both more effective and less
expensive biologically based treatments. Our understanding of the
pathophysiology of the disease is increasing as new biochemical pathways ... Cited by 9 - Related articles - BL Direct - All 5 versions
MC Hernaez-Ortega, E Soto-Pedre, JJB … - Diabetes research and clinical practice, 2004 - Elsevier We report the clinical outcome of a 46-year-old diabetic patient with cystoid
macular edema treated with Sandostatin ® long-acting release (LAR). Because
cystoid changes in both eyes were refractive to conventional treatment (ie, ... Cited by 11 - Related articles - All 8 versions
- ►iovs.org DD Klisovic, MS O'Dorisio, SE Katz, JW Sall, … - Investigative ophthalmology & visual science, 2001 - ARVO PURPOSE. Somatostatin (SST) analogues have been used to treat proliferative
diabetic retinopathy, pseudotumor cerebri, thyroid orbitopathy, and cystoid
macular edema. There is a paucity of published data in regards to ... Cited by 36 - Related articles - BL Direct - All 3 versions
